Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-NHL 2013 in pediatric mature aggressive B-cell lymphoma/leukemia
2013-003253-21Phase 3Active
- Sponsor
- Universitätsklinikum Münster
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab in mature B-cell lymphoma, Burkitt lymphoma (BL), Burkitt leukemia and 1 more, sponsored by Universitätsklinikum Münster. Primary endpoint: Event-free survival. Started Dec 2016; status: active.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2013-003253-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003253-21.